The overall ratings of six Biotechnology stocks are down on Portfolio Grader this week. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).
This week, Cepheid (NASDAQ:CPHD) falls to a D (“sell”), worse than last week’s grade of C (“hold”). Cepheid is a molecular diagnostics company that engages in developing, manufacturing, and marketing integrated systems for testing in the clinical market, as well as for application in legacy biothreat, industrial, and partner markets. In Portfolio Grader’s specific subcategories of Earnings Revisions, Earnings Surprise, and Margin Growth, CPHD also gets an F. As of Sept. 26, 2012, 14.8% of outstanding Cepheid shares were held short. For more information, get Portfolio Grader’s complete analysis of CPHD stock.
The rating of ArQule (NASDAQ:ARQL) slips from a C to a D. ArQule is a biotechnology company that is engaged in the research and development of cancer therapeutics. The stock also rates an F in Equity. The stock price has dropped 26.4% over the past month, worse than the 1.6% increase the Nasdaq has seen over the same period of time. To get an in-depth look at ARQL, get Portfolio Grader’s complete analysis of ARQL stock.
MannKind (NASDAQ:MNKD) earns a D this week, falling from last week’s grade of C. MannKind is a biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The stock also gets an F in Cash Flow. As of Sept. 26, 2012, 15% of outstanding MannKind shares were held short. For more information, get Portfolio Grader’s complete analysis of MNKD stock.
Progenics Pharmaceuticals (NASDAQ:PGNX) ratings are on the decline this week as the company earns a F (“strong sell”). Last week, it received a D (“sell”). Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The stock gets F’s in Earnings Growth, Earnings Momentum, and Earnings Revisions. Equity, Cash Flow, and Sales Growth also get F’s. The stock price has fallen 23.3% over the past month. To get an in-depth look at PGNX, get Portfolio Grader’s complete analysis of PGNX stock.
Aegerion Pharmaceuticals (NASDAQ:AEGR) is having a tough week. The company’s rating falls from a C to a D rating. Aegerion Pharmaceuticals is an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat severe lipid disorders. The stock gets F’s in Equity and Cash Flow. For a full analysis of AEGR stock, visit Portfolio Grader.
PROLOR Biotech (AMEX:PBTH) gets weaker ratings this week as last week’s C drops to a D. PROLOR Biotech offers treatment by using naturally occurring amino acid sequence to slow the removal of therapeutic proteins from the body without increasing toxicity or altering the overall biological activity. The stock also gets an F in Equity. To get an in-depth look at PBTH, get Portfolio Grader’s complete analysis of PBTH stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.